Skip to main content
Premium Trial:

Request an Annual Quote

SAIC-Frederick Will Integrate Geospiza Software with PacBio Sequencing for Cancer Research

Premium

Software company Geospiza said this week that cancer and AIDS research institute SAIC-Frederick will integrate its genetic-analysis software with SAIC-Frederick's Pacific Biosciences sequencer to help perform cancer research.

Geospiza's GeneSifter Lab Edition software is already compatible with Illumina, Life Technologies' SOLiD, and Helicos sequencing platforms.

SAIC-Frederick, which currently uses the software with those machines, will help make it compatible with Pac Bio's Single Molecule Real Time Sequencing technology.

SAIC-Frederick, a subsidiary of Science Applications International Cooperation and a contractor of the National Cancer Institute, penned the deal as part of NCI's Advanced Technology Partnerships Initiative, which "seeks to reduce the time and cost of developing new cancer treatments," according to a statement.

"Having in place a rapid, third-generation sequencing system is expected to accelerate studies into the genetic basis of cancer and to pave the way for more effective treatments," Geospiza said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.